[EBV-specific antibodies in patients with nasopharyngeal cancer and tonsillar cancer. Follow-up of over 4 years].
26 NPC patients and 47 TC patients were investigated clinically, and in the sera of these patients EBV-specific antibodies were determined. No relapse occurred in 11 patients with NPC and in 17 patients with TC during the period of 4 years. In addition to the determination of antibodies we looked for EBNA in 3 undifferentiated NPC and 4 undifferentiated TC, and for EBV-DNA in 2 of these NPC and one of these TC. The 3 NPC and 4 TC tested for EBNA showed this antigen in the cells. 2 NPC and 1 TC showed EBV-DNA with in situ hybridization technique. In the blot hybridization according to Southern the Eco R 1 fragment of both NPC was identical with the Eco R 1 fragment of the positive control of P 3 HR 1 cells. The 15 NPC-patients with tumour (4 with primary NPC, 11 with relapse) in the observation period showed higher IgA-VCA titres than the NPC patients free of relapse during this time. Subsequent to therapy, IgG-VCA titres decreased. Most of the NPC-patients with tumour during the time of testing mentioned before had IgA-VCA once or several times. Most of half of these patients had IgA-EA, but there was no patient without relapse. IgA-VCA increase and the presence of IgA-EA may be the first sign of a relapse. Thus, intensive research into this phenomenon will be required. No remarkable difference could be found in EBV-specific antibody patterns between TC patients without relapse and TC patients with tumour progression or relapse.